Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.77 | N/A | +18.64% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.77 | N/A | +18.64% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed satisfaction with the earnings beat. They emphasized their commitment to maintaining momentum in their product pipeline.
The company is pleased with the EPS performance this quarter.
Management highlighted ongoing efforts to drive growth in key therapeutic areas.
Bristol Myers Squibb's strong EPS performance indicates effective cost management and potentially robust product sales. The stock's 5.42% increase reflects investor confidence following the earnings beat. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RESTAURANT BRANDS IN
Oct 24, 2016